INNV-13. Real-world outcomes in patients with brain metastases secondary to melanoma treated with nivolumab and relatlimab Article Swipe
Erika Yamazawa
,
Justine V. Cohen
,
Elizabeth Summers
,
Hannah Mae Faulkner
,
Ryan J. Sullivan
,
Michael P. Manos
,
Julie Fishman
,
Aleigha Lawless
,
Anita Giobbie‐Hurder
,
Meghan J. Mooradian
,
Elizabeth I. Buchbinder
,
Priscilla K. Brastianos
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1093/neuonc/noaf201.0902
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1093/neuonc/noaf201.0902
PURPOSE Patients with melanoma brain metastases (MBM) have a poor prognosis despite improvements in treatments. The combination of ipilimumab and nivolumab remains the standard of care for this patient population and there is limited data on the combination of nivolumab and relatlimab (nivo-rela) in MBM. PATIENTS AND METHODS We performed a retrospective cohort study of patients with MBM treated with nivo-rela from May 2022 to December 2023 at two academic institutions in Boston, MA. Information pertaining to patient demographics, survival, timing of therapy (radiation, nivo-rela), response rates and adverse events were collected. Progression-free survival and overall survival were calculated. RESULTS A total of 39 patients were identified with a median follow-up of 26 months. Most patients were male (25 of 39 [64.1%]), with a median age of 69 years (range 31-87 years). Estimated survival rates were 79% (95% CI: 63% to 89%) at one year and 69% (95% CI: 50% to 82%) at two years following MBM diagnosis. We saw intracranial clinical benefit (response or stable disease) in 19 of 39 (48.7%) patients. Extracranial response was largely concordant with intracranial benefit with durable clinical benefit, defined as CR, PR or SD for 6 months, in 14 of 39 (35.9%) patients. A total of 30 patients (77%) received radiation therapy (SRT or both WBRT and SRT). Among them, 46.7% (14 of 30) showed either a decrease or stable intracranial disease after starting nivo-rela, compared to 55.6% (5 of 9) in the non-radiation therapy group. CONCLUSION The combination of nivo-rela showed intracranial activity in patients with MBM, particularly in the front-line setting. Prospective trials are needed to validate these findings and provide data on the optimal use of systemic and local therapies in this challenging patient population.
Related Topics
Concepts
No concepts available.
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/neuonc/noaf201.0902
- https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v227/65255865/noaf201.0902.pdf
- OA Status
- bronze
- OpenAlex ID
- https://openalex.org/W4416085003
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4416085003Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/neuonc/noaf201.0902Digital Object Identifier
- Title
-
INNV-13. Real-world outcomes in patients with brain metastases secondary to melanoma treated with nivolumab and relatlimabWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-11-01Full publication date if available
- Authors
-
Erika Yamazawa, Justine V. Cohen, Elizabeth Summers, Hannah Mae Faulkner, Ryan J. Sullivan, Michael P. Manos, Julie Fishman, Aleigha Lawless, Anita Giobbie‐Hurder, Meghan J. Mooradian, Elizabeth I. Buchbinder, Priscilla K. BrastianosList of authors in order
- Landing page
-
https://doi.org/10.1093/neuonc/noaf201.0902Publisher landing page
- PDF URL
-
https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v227/65255865/noaf201.0902.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v227/65255865/noaf201.0902.pdfDirect OA link when available
- Cited by
-
0Total citation count in OpenAlex
Full payload
| id | https://openalex.org/W4416085003 |
|---|---|
| doi | https://doi.org/10.1093/neuonc/noaf201.0902 |
| ids.doi | https://doi.org/10.1093/neuonc/noaf201.0902 |
| ids.openalex | https://openalex.org/W4416085003 |
| fwci | 0.0 |
| type | article |
| title | INNV-13. Real-world outcomes in patients with brain metastases secondary to melanoma treated with nivolumab and relatlimab |
| biblio.issue | Supplement_5 |
| biblio.volume | 27 |
| biblio.last_page | v227 |
| biblio.first_page | v227 |
| is_xpac | False |
| apc_list.value | 4612 |
| apc_list.currency | USD |
| apc_list.value_usd | 4612 |
| apc_paid | |
| language | en |
| locations[0].id | doi:10.1093/neuonc/noaf201.0902 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S106908163 |
| locations[0].source.issn | 1522-8517, 1523-5866 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1522-8517 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Neuro-Oncology |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648 |
| locations[0].license | |
| locations[0].pdf_url | https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v227/65255865/noaf201.0902.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Neuro-Oncology |
| locations[0].landing_page_url | https://doi.org/10.1093/neuonc/noaf201.0902 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5012959798 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-3079-2331 |
| authorships[0].author.display_name | Erika Yamazawa |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[0].affiliations[0].raw_affiliation_string | Massachusetts General Hospital, Boston, USA |
| authorships[0].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[0].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Massachusetts General Hospital |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Erika Yamazawa |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Massachusetts General Hospital, Boston, USA |
| authorships[1].author.id | https://openalex.org/A5046320640 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-4803-9230 |
| authorships[1].author.display_name | Justine V. Cohen |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[1].affiliations[0].raw_affiliation_string | Dana Farber Cancer Institute, Boston, USA |
| authorships[1].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[1].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[1].institutions[0].type | facility |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Justine Cohen |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Dana Farber Cancer Institute, Boston, USA |
| authorships[2].author.id | https://openalex.org/A5032028131 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Elizabeth Summers |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[2].affiliations[0].raw_affiliation_string | Massachusetts General Hospital, Boston, USA |
| authorships[2].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[2].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Massachusetts General Hospital |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Elizabeth Summers |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Massachusetts General Hospital, Boston, USA |
| authorships[3].author.id | https://openalex.org/A5116047430 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Hannah Mae Faulkner |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[3].affiliations[0].raw_affiliation_string | Dana Farber Cancer Institute, Boston, USA |
| authorships[3].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[3].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[3].institutions[0].type | facility |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Hannah Faulkner |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Dana Farber Cancer Institute, Boston, USA |
| authorships[4].author.id | https://openalex.org/A5008479799 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-5344-6645 |
| authorships[4].author.display_name | Ryan J. Sullivan |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[4].affiliations[0].raw_affiliation_string | Massachusetts General Hospital, Boston, USA |
| authorships[4].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[4].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Massachusetts General Hospital |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Ryan Sullivan |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Massachusetts General Hospital, Boston, USA |
| authorships[5].author.id | https://openalex.org/A5070590609 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-0841-207X |
| authorships[5].author.display_name | Michael P. Manos |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[5].affiliations[0].raw_affiliation_string | Dana Farber Cancer Institute, Boston, USA |
| authorships[5].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[5].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[5].institutions[0].type | facility |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Michael Manos |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Dana Farber Cancer Institute, Boston, USA |
| authorships[6].author.id | https://openalex.org/A5065181027 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Julie Fishman |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I57206974 |
| authorships[6].affiliations[0].raw_affiliation_string | New York University Grossman School of Medicine, New York, USA |
| authorships[6].institutions[0].id | https://openalex.org/I57206974 |
| authorships[6].institutions[0].ror | https://ror.org/0190ak572 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I57206974 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | New York University |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Julie Fishman |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | New York University Grossman School of Medicine, New York, USA |
| authorships[7].author.id | https://openalex.org/A5089902724 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Aleigha Lawless |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[7].affiliations[0].raw_affiliation_string | Massachusetts General Hospital, Boston, USA |
| authorships[7].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[7].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Massachusetts General Hospital |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Aleigha Lawless |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Massachusetts General Hospital, Boston, USA |
| authorships[8].author.id | https://openalex.org/A5071788399 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-2496-7737 |
| authorships[8].author.display_name | Anita Giobbie‐Hurder |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[8].affiliations[0].raw_affiliation_string | Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, USA |
| authorships[8].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[8].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[8].institutions[0].type | facility |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Anita Giobbie-Hurder |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, USA |
| authorships[9].author.id | https://openalex.org/A5083431383 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-8289-8015 |
| authorships[9].author.display_name | Meghan J. Mooradian |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[9].affiliations[0].raw_affiliation_string | Massachusetts General Hospital, Boston, USA |
| authorships[9].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[9].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Massachusetts General Hospital |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Meghan Mooradian |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Massachusetts General Hospital, Boston, USA |
| authorships[10].author.id | https://openalex.org/A5066489948 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-7979-8953 |
| authorships[10].author.display_name | Elizabeth I. Buchbinder |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210117453 |
| authorships[10].affiliations[0].raw_affiliation_string | Dana Farber Cancer Institute, Boston, USA |
| authorships[10].institutions[0].id | https://openalex.org/I4210117453 |
| authorships[10].institutions[0].ror | https://ror.org/02jzgtq86 |
| authorships[10].institutions[0].type | facility |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210117453 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | Dana-Farber Cancer Institute |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Elizabeth Buchbinder |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Dana Farber Cancer Institute, Boston, USA |
| authorships[11].author.id | https://openalex.org/A5015428519 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-4470-8425 |
| authorships[11].author.display_name | Priscilla K. Brastianos |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[11].affiliations[0].raw_affiliation_string | Massachusetts General Hospital, Boston, USA |
| authorships[11].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[11].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[11].institutions[0].type | healthcare |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | Massachusetts General Hospital |
| authorships[11].author_position | last |
| authorships[11].raw_author_name | Priscilla Brastianos |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Massachusetts General Hospital, Boston, USA |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v227/65255865/noaf201.0902.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-11-11T00:00:00 |
| display_name | INNV-13. Real-world outcomes in patients with brain metastases secondary to melanoma treated with nivolumab and relatlimab |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-28T09:29:04.333110 |
| primary_topic | |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1093/neuonc/noaf201.0902 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S106908163 |
| best_oa_location.source.issn | 1522-8517, 1523-5866 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1522-8517 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Neuro-Oncology |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v227/65255865/noaf201.0902.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Neuro-Oncology |
| best_oa_location.landing_page_url | https://doi.org/10.1093/neuonc/noaf201.0902 |
| primary_location.id | doi:10.1093/neuonc/noaf201.0902 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S106908163 |
| primary_location.source.issn | 1522-8517, 1523-5866 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1522-8517 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Neuro-Oncology |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| primary_location.license | |
| primary_location.pdf_url | https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v227/65255865/noaf201.0902.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Neuro-Oncology |
| primary_location.landing_page_url | https://doi.org/10.1093/neuonc/noaf201.0902 |
| publication_date | 2025-11-01 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.6 | 193 |
| abstract_inverted_index.A | 101, 201 |
| abstract_inverted_index.a | 9, 51, 109, 124, 224 |
| abstract_inverted_index.(5 | 236 |
| abstract_inverted_index.14 | 196 |
| abstract_inverted_index.19 | 169 |
| abstract_inverted_index.26 | 113 |
| abstract_inverted_index.30 | 204 |
| abstract_inverted_index.39 | 104, 121, 171, 198 |
| abstract_inverted_index.69 | 128 |
| abstract_inverted_index.9) | 238 |
| abstract_inverted_index.PR | 189 |
| abstract_inverted_index.SD | 191 |
| abstract_inverted_index.We | 49, 159 |
| abstract_inverted_index.as | 187 |
| abstract_inverted_index.at | 68, 143, 153 |
| abstract_inverted_index.in | 14, 44, 72, 168, 195, 239, 252, 257, 281 |
| abstract_inverted_index.is | 33 |
| abstract_inverted_index.of | 18, 25, 39, 55, 82, 103, 112, 120, 127, 170, 197, 203, 220, 237, 247, 276 |
| abstract_inverted_index.on | 36, 272 |
| abstract_inverted_index.or | 165, 190, 211, 226 |
| abstract_inverted_index.to | 65, 77, 141, 151, 234, 265 |
| abstract_inverted_index.(14 | 219 |
| abstract_inverted_index.(25 | 119 |
| abstract_inverted_index.30) | 221 |
| abstract_inverted_index.50% | 150 |
| abstract_inverted_index.63% | 140 |
| abstract_inverted_index.69% | 147 |
| abstract_inverted_index.79% | 137 |
| abstract_inverted_index.AND | 47 |
| abstract_inverted_index.CI: | 139, 149 |
| abstract_inverted_index.CR, | 188 |
| abstract_inverted_index.MA. | 74 |
| abstract_inverted_index.MBM | 58, 157 |
| abstract_inverted_index.May | 63 |
| abstract_inverted_index.The | 16, 245 |
| abstract_inverted_index.age | 126 |
| abstract_inverted_index.and | 20, 31, 41, 88, 95, 146, 214, 269, 278 |
| abstract_inverted_index.are | 263 |
| abstract_inverted_index.for | 27, 192 |
| abstract_inverted_index.one | 144 |
| abstract_inverted_index.saw | 160 |
| abstract_inverted_index.the | 23, 37, 240, 258, 273 |
| abstract_inverted_index.two | 69, 154 |
| abstract_inverted_index.use | 275 |
| abstract_inverted_index.was | 176 |
| abstract_inverted_index.(95% | 138, 148 |
| abstract_inverted_index.(SRT | 210 |
| abstract_inverted_index.2022 | 64 |
| abstract_inverted_index.2023 | 67 |
| abstract_inverted_index.82%) | 152 |
| abstract_inverted_index.89%) | 142 |
| abstract_inverted_index.MBM, | 255 |
| abstract_inverted_index.MBM. | 45 |
| abstract_inverted_index.Most | 115 |
| abstract_inverted_index.WBRT | 213 |
| abstract_inverted_index.both | 212 |
| abstract_inverted_index.care | 26 |
| abstract_inverted_index.data | 35, 271 |
| abstract_inverted_index.from | 62 |
| abstract_inverted_index.have | 8 |
| abstract_inverted_index.male | 118 |
| abstract_inverted_index.poor | 10 |
| abstract_inverted_index.this | 28, 282 |
| abstract_inverted_index.were | 91, 98, 106, 117, 136 |
| abstract_inverted_index.with | 3, 57, 60, 108, 123, 179, 182, 254 |
| abstract_inverted_index.year | 145 |
| abstract_inverted_index.(77%) | 206 |
| abstract_inverted_index.(MBM) | 7 |
| abstract_inverted_index.31-87 | 131 |
| abstract_inverted_index.46.7% | 218 |
| abstract_inverted_index.55.6% | 235 |
| abstract_inverted_index.Among | 216 |
| abstract_inverted_index.SRT). | 215 |
| abstract_inverted_index.after | 230 |
| abstract_inverted_index.brain | 5 |
| abstract_inverted_index.local | 279 |
| abstract_inverted_index.rates | 87, 135 |
| abstract_inverted_index.study | 54 |
| abstract_inverted_index.them, | 217 |
| abstract_inverted_index.there | 32 |
| abstract_inverted_index.these | 267 |
| abstract_inverted_index.total | 102, 202 |
| abstract_inverted_index.years | 129, 155 |
| abstract_inverted_index.(range | 130 |
| abstract_inverted_index.cohort | 53 |
| abstract_inverted_index.either | 223 |
| abstract_inverted_index.events | 90 |
| abstract_inverted_index.group. | 243 |
| abstract_inverted_index.median | 110, 125 |
| abstract_inverted_index.needed | 264 |
| abstract_inverted_index.showed | 222, 249 |
| abstract_inverted_index.stable | 166, 227 |
| abstract_inverted_index.timing | 81 |
| abstract_inverted_index.trials | 262 |
| abstract_inverted_index.(35.9%) | 199 |
| abstract_inverted_index.(48.7%) | 172 |
| abstract_inverted_index.Boston, | 73 |
| abstract_inverted_index.METHODS | 48 |
| abstract_inverted_index.PURPOSE | 1 |
| abstract_inverted_index.RESULTS | 100 |
| abstract_inverted_index.adverse | 89 |
| abstract_inverted_index.benefit | 163, 181 |
| abstract_inverted_index.defined | 186 |
| abstract_inverted_index.despite | 12 |
| abstract_inverted_index.disease | 229 |
| abstract_inverted_index.durable | 183 |
| abstract_inverted_index.largely | 177 |
| abstract_inverted_index.limited | 34 |
| abstract_inverted_index.months, | 194 |
| abstract_inverted_index.months. | 114 |
| abstract_inverted_index.optimal | 274 |
| abstract_inverted_index.overall | 96 |
| abstract_inverted_index.patient | 29, 78, 284 |
| abstract_inverted_index.provide | 270 |
| abstract_inverted_index.remains | 22 |
| abstract_inverted_index.therapy | 83, 209, 242 |
| abstract_inverted_index.treated | 59 |
| abstract_inverted_index.years). | 132 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.December | 66 |
| abstract_inverted_index.PATIENTS | 46 |
| abstract_inverted_index.Patients | 2 |
| abstract_inverted_index.academic | 70 |
| abstract_inverted_index.activity | 251 |
| abstract_inverted_index.benefit, | 185 |
| abstract_inverted_index.clinical | 162, 184 |
| abstract_inverted_index.compared | 233 |
| abstract_inverted_index.decrease | 225 |
| abstract_inverted_index.disease) | 167 |
| abstract_inverted_index.findings | 268 |
| abstract_inverted_index.melanoma | 4 |
| abstract_inverted_index.patients | 56, 105, 116, 205, 253 |
| abstract_inverted_index.received | 207 |
| abstract_inverted_index.response | 86, 175 |
| abstract_inverted_index.setting. | 260 |
| abstract_inverted_index.standard | 24 |
| abstract_inverted_index.starting | 231 |
| abstract_inverted_index.survival | 94, 97, 134 |
| abstract_inverted_index.systemic | 277 |
| abstract_inverted_index.validate | 266 |
| abstract_inverted_index.(response | 164 |
| abstract_inverted_index.Estimated | 133 |
| abstract_inverted_index.[64.1%]), | 122 |
| abstract_inverted_index.follow-up | 111 |
| abstract_inverted_index.following | 156 |
| abstract_inverted_index.nivo-rela | 61, 248 |
| abstract_inverted_index.nivolumab | 21, 40 |
| abstract_inverted_index.patients. | 173, 200 |
| abstract_inverted_index.performed | 50 |
| abstract_inverted_index.prognosis | 11 |
| abstract_inverted_index.radiation | 208 |
| abstract_inverted_index.survival, | 80 |
| abstract_inverted_index.therapies | 280 |
| abstract_inverted_index.CONCLUSION | 244 |
| abstract_inverted_index.collected. | 92 |
| abstract_inverted_index.concordant | 178 |
| abstract_inverted_index.diagnosis. | 158 |
| abstract_inverted_index.front-line | 259 |
| abstract_inverted_index.identified | 107 |
| abstract_inverted_index.ipilimumab | 19 |
| abstract_inverted_index.metastases | 6 |
| abstract_inverted_index.nivo-rela, | 232 |
| abstract_inverted_index.pertaining | 76 |
| abstract_inverted_index.population | 30 |
| abstract_inverted_index.relatlimab | 42 |
| abstract_inverted_index.(nivo-rela) | 43 |
| abstract_inverted_index.(radiation, | 84 |
| abstract_inverted_index.Information | 75 |
| abstract_inverted_index.Prospective | 261 |
| abstract_inverted_index.calculated. | 99 |
| abstract_inverted_index.challenging | 283 |
| abstract_inverted_index.combination | 17, 38, 246 |
| abstract_inverted_index.nivo-rela), | 85 |
| abstract_inverted_index.population. | 285 |
| abstract_inverted_index.treatments. | 15 |
| abstract_inverted_index.Extracranial | 174 |
| abstract_inverted_index.improvements | 13 |
| abstract_inverted_index.institutions | 71 |
| abstract_inverted_index.intracranial | 161, 180, 228, 250 |
| abstract_inverted_index.particularly | 256 |
| abstract_inverted_index.demographics, | 79 |
| abstract_inverted_index.non-radiation | 241 |
| abstract_inverted_index.retrospective | 52 |
| abstract_inverted_index.Progression-free | 93 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 12 |
| citation_normalized_percentile |